Melphalan, Antimelanoma Immunity, and Inflammation--Response

Cancer Res. 2015 Dec 15;75(24):5400-1. doi: 10.1158/0008-5472.CAN-15-2061. Epub 2015 Dec 1.

Authors

Abhishek D Garg¹, Aleksandra M Dudek-Peric¹, Patrizia Agostinis²

Affiliations

¹ Cell Death Research and Therapy (CDRT) Lab, Department of Cellular Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium.
² Cell Death Research and Therapy (CDRT) Lab, Department of Cellular Molecular Medicine, KU Leuven University of Leuven, Leuven, Belgium. patrizia.agostinis@med.kuleuven.be.

PMID: 26627014
DOI: 10.1158/0008-5472.CAN-15-2061

No abstract available

Publication types

Letter
Comment

MeSH terms

Animals
Antigens, Surface / physiology*
Antineoplastic Agents, Alkylating / pharmacology*
Calreticulin / physiology*
Humans
Melanoma / immunology*
Melphalan / pharmacology*
Skin Neoplasms / immunology*

Substances

Antigens, Surface
Antineoplastic Agents, Alkylating
Calreticulin
Melphalan